ライフサイエンスコーパス: pulmonary embolism

1 the deep veins, one peripheral vein and one pulmonary embolism).

2 mboembolic events (deep venous thrombosis or pulmonary embolism).

3 e) and two PCC related (ischaemic stroke and pulmonary embolism).

4 ry angiography was performed to evaluate for pulmonary embolism.

5 ctor for deep vein thrombosis of the leg and pulmonary embolism.

6 ment of the pulmonary trunk to investigate a pulmonary embolism.

7 ired infections, venous thromboembolism, and pulmonary embolism.

8 ay of treatment for deep vein thrombosis and pulmonary embolism.

9 ciated with certain causes of arrest such as pulmonary embolism.

10 dentification of PH after exclusion of acute pulmonary embolism.

11 rotected mice from prostasome-induced lethal pulmonary embolism.

12 ombosis can lead to deep-vein thrombosis and pulmonary embolism.

13 venous thromboembolic events with or without pulmonary embolism.

14 nt travel history, there was suspicion for a pulmonary embolism.

15 nts, as well as for deep vein thrombosis and pulmonary embolism.

16 usceptible than Par4(-/-) mice to TF-induced pulmonary embolism.

17 with symptoms of acute coronary syndrome and pulmonary embolism.

18 g and life-threatening complication of acute pulmonary embolism.

19 ms suggestive of acute coronary syndrome and pulmonary embolism.

20 thrombosis can cause venous obstruction and pulmonary embolism.

21 normotensive patients with intermediate-risk pulmonary embolism.

22 as no evidence of an effect of statin use on pulmonary embolism.

23 med on pregnant patients suspected of having pulmonary embolism.

24 ith CTEPH have a history of clinically overt pulmonary embolism.

25 inclusion of patients with intermediate-risk pulmonary embolism.

26 icial in the treatment of some patients with pulmonary embolism.

27 d with deep-vein thrombosis, and 3319 with a pulmonary embolism.

28 t increased risk of deep vein thrombosis and pulmonary embolism.

29 thromboembolism, including those with severe pulmonary embolism.

30 decreases pulmonary embolism and symptomatic pulmonary embolism.

31 sis, device migration, caval penetration, or pulmonary embolism.

32 pulations for the prophylactic prevention of pulmonary embolism.

33 ce of PPCs, pleural effusion, pneumonia, and pulmonary embolism.

34 han those with left DVT to have a history of pulmonary embolism.

35 osing right ventricular dysfunction in acute pulmonary embolism.

36 uding 20 (61%) with no clinical suspicion of pulmonary embolism.

37 been shown not to be always the same as for pulmonary embolism.

38 py results in the accelerated lysis of acute pulmonary embolism.

39 approach may also simplify the treatment of pulmonary embolism.

40 cted from experimental cerebral ischemia and pulmonary embolism.

41 Adult in/outpatients diagnosed with acute pulmonary embolism.

42 VTE complication, including 51 patents with pulmonary embolism.

43 anticoagulant use was not a risk factor for pulmonary embolism.

44 s are available faster than CCTs and predict pulmonary embolism.

45 of the use of thrombolytic therapy in acute pulmonary embolism.

46 eeding were examined in a humanized model of pulmonary embolism.

47 esuscitation is particularly associated with pulmonary embolism.

48 tical care physicians in patients with acute pulmonary embolism.

49 lar size and function in patients with acute pulmonary embolism.

50 ating right ventricular dysfunction in acute pulmonary embolism.

51 d, deep-vein thrombosis in the arm or leg or pulmonary embolism.

52 lasmin, may have unique therapeutic value in pulmonary embolism.

53 alysis focuses on the included patients with pulmonary embolism.

54 with severe disease, have increased risk of pulmonary embolism.

55 er use did not reduce the risk of subsequent pulmonary embolism.

56 3319 patients had pulmonary embolism.

57 d to identify and treat patients at risk for pulmonary embolism.

58 pulmonary arterial system is referred to as pulmonary embolism.

59 r extremity thrombosis (0.77% versus 0.96%), pulmonary embolism (0.38% versus 0.96%), or urgent surge

60 ia (2.3%), hemorrhage or hematoma (1.4%), or pulmonary embolism (0.6%).

61 mbosis (4), transitory ischemic attacks (2), pulmonary embolism (1), and arterial aneurysm (1).

62 43; 95% CI, 0.36-0.52; P<0.01; I(2)=34%) and pulmonary embolism (1.2% versus 2.8%; absolute risk redu

63 (31%), neutropenia (23%), anemia (15%), and pulmonary embolism (12%).

64 The rates of pulmonary embolism (12.1% versus 7.8%; P=0.02), intracra

65 6%), other GI toxicity (4%), infection (4%), pulmonary embolism (2%), and cardiac ischemia (2%).

66 yed fixation suffered 2-fold higher rates of pulmonary embolism (2.6% versus 1.3%; rate ratio [RR] 2.

67 d possibly or probably related to treatment (pulmonary embolism [200 mg/day], respiratory failure [12

68 1, OR 0.85, 95% CI 0.72-1.01) and effects on pulmonary embolism (205 versus 222, OR 0.92, 95% CI 0.76

69 participants; OR, 0.25; 95% CI, 0.09-0.72), pulmonary embolism (3 studies, 237 participants; OR, 0.0

70 (7.1%), cerebrovascular disease (5.8%), and pulmonary embolism (3.7%).

71 ne [2%]), asthenia (27 [5%] vs 17 [3%]), and pulmonary embolism (32 [6%] vs seven [1%]) occurred more

72 ine [1%]), fatigue (50 [6%] vs 14 [2%]), and pulmonary embolism (40 [5%] vs 27 [4%]).

73 public awareness is substantially lower for pulmonary embolism (54%) and deep-vein thrombosis (44%)

74 thrombosis (12 more per 10 000 woman-years), pulmonary embolism (9 more per 10 000 woman-years), lung

75 The prevalence of pulmonary embolism among patients hospitalized for synco

76 s thromboembolism (which comprised events of pulmonary embolism and deep-vein thrombosis) was more co

77 These findings suggest that pulmonary embolism and DVT may not always have the same

78 63+/-14 years) with acute main or lower lobe pulmonary embolism and echocardiographic RV to left vent

79 rent venous thromboembolism in patients with pulmonary embolism and evidence of right ventricular dys

80 Two dose-limiting toxicities (grade 2 pulmonary embolism and grade 4 hypocellular marrow) occu

81 y for the initial and long-term treatment of pulmonary embolism and had a potentially improved benefi

82 ion of a low pretest clinical probability of pulmonary embolism and negative d-dimer assay.

83 es of pulmonary clots for differentiation of pulmonary embolism and postmortem organized thrombus wer

84 common were at significantly greater risk of pulmonary embolism and required longer hospital stay.

85 thrombolytic agents, but patients with acute pulmonary embolism and significant compromise in the abs

86 timates for both acute coronary syndrome and pulmonary embolism and suggested clinical actions design

87 ed with bid unfractionated heparin decreases pulmonary embolism and symptomatic pulmonary embolism.

88 nd readily available, the rapid diagnosis of pulmonary embolism and use of thrombolytics during cardi

89 infarction, stroke, deep vein thrombosis, or pulmonary embolism) and haemorrhagic events (symptomatic

90 nary embolism, one bronchopneumonia, and one pulmonary embolism) and one in the chemotherapy alone gr

91 h cancer who had recurrent VTE (particularly pulmonary embolism) and with bleeding on anticoagulation

92 y heart disease, invasive breast cancer, and pulmonary embolism), and raloxifene (venous thromboembol

93 ent), venous events (deep vein thrombosis or pulmonary embolism), and respiratory events (pneumonia,

94 ished VTE risk factors), and unprovoked VTE, pulmonary embolism, and deep-vein thrombosis.

95 adjudicated recurrent DVT, fatal or nonfatal pulmonary embolism, and incidental VTE.

96 Mortality, intracranial bleeding, pulmonary embolism, and MI were lower with dabigatran, c

97 ficiency or failure, venous thromboembolism, pulmonary embolism, and operative complications.

98 myocardial infarction, deep vein thrombosis, pulmonary embolism, and pneumonia).

99 Of these, 3 events-syncope, pulmonary embolism, and serum creatinine increase-in 3 p

100 d with pulmonary surgery, those who suffered pulmonary embolism, and those in the IGCCCG poor prognos

101 ailure, atrial fibrillation, cardiac arrest, pulmonary embolism, and/or stroke).

102 Deep vein thrombosis (DVT) and pulmonary embolism are collectively known as venous thro

103 ion, stroke, transient ischemic attacks, and pulmonary embolism are major causes of morbidity and mor

104 Deep vein thrombosis and pulmonary embolism are major health problems associated

105 ys of treatment for deep vein thrombosis and pulmonary embolism as well as for long-term (6 months) s

106 ys of treatment for deep vein thrombosis and pulmonary embolism as well as for long-term secondary pr

107 ospitalized patients with acute, symptomatic pulmonary embolism associated with lower-limb vein throm

108 f deep vein thrombosis or non-fatal or fatal pulmonary embolism at 12 months.

109 not reduce the risk of symptomatic recurrent pulmonary embolism at 3 months.

110 y efficacy outcome was symptomatic recurrent pulmonary embolism at 3 months.

111 Secondary outcomes were recurrent pulmonary embolism at 6 months, symptomatic deep vein th

112 In patients with pulmonary embolism at intermediate risk, a standardized

113 esence or absence of deep vein thrombosis or pulmonary embolism at the time of IVC filter placement.

114 ism (which includes deep vein thrombosis and pulmonary embolism), but the evidence is uncertain.

115 rs with an opposite effect: a higher risk of pulmonary embolism, but little or no effect on DVT.

116 When pulmonary embolism coexists with a patent foramen ovale,

117 A global index also included stroke, pulmonary embolism, colorectal cancer, endometrial cance

118 uscitation when cardiac arrest was caused by pulmonary embolism compared with hypoxia and primary arr

119 resuscitation from cardiac arrest caused by pulmonary embolism, compared with hypoxia and primary ar

120 rial thromboses and deep-vein thrombosis and pulmonary embolism comprise venous thromboembolism.

121 of symptomatic VTE (deep vein thrombosis and pulmonary embolism, confirmed by duplex ultrasonography

122 Finally, complications (pulmonary embolism, deep vein thrombosis, acute respirat

123 ty of DOACs were consistent in patients with pulmonary embolism, deep venous thrombosis, a body weigh

124 actionated heparin for preventing mortality, pulmonary embolism, deep venous thrombosis, bleeding out

125 WH) or unfractionated heparin and mortality, pulmonary embolism, deep venous thrombosis, thrombocytop

126 Other risks included increased stroke, pulmonary embolism, dementia (in women aged >/=65 years)

127 lism, proximal leg deep vein thrombosis, and pulmonary embolism developing during critical illness we

128 Of 176 included patients, 33 (18.7%) had pulmonary embolism diagnosed by computed tomography, inc

129 criteria, 35%; Prospective Investigation of Pulmonary Embolism Diagnosis study, 29%; no standardized

130 anticoagulation was given immediately after pulmonary embolism diagnosis.

131 In our case, we found both pulmonary embolism due to DVT and paradoxical embolism d

132 ulprit emboli after deep vein thrombosis and pulmonary embolism (DVT-PE).

133 with deep-vein thrombosis (EINSTEIN-DVT) or pulmonary embolism (EINSTEIN-PE) were randomly assigned

134 In patients with intermediate-risk pulmonary embolism, fibrinolytic therapy prevented hemod

135 he device is effective for the prevention of pulmonary embolism for at least 5 weeks after placement

136 omputed tomography pulmonary angiography for pulmonary embolism) for those with a high pretest probab

137 iterans from chronic rejection and by recent pulmonary embolism, for which she was undergoing anticoa

138 s suspected to be related to study drug were pulmonary embolism (four patients; 8%), vomiting (four;

139 ps for major bleeding, from 0.2% to 0.9% for pulmonary embolism, from 0.1% to 0.7% for periprocedural

140 m cardiac arrest with contributing reason of pulmonary embolism (grade 4, suspected to be study drug

141 By 3 months, recurrent pulmonary embolism had occurred in 6 patients (3.0%; all

142 A total of 938 patients with pulmonary embolism had right ventricular dysfunction, as

143 Patients with acute pulmonary embolism had the lowest insulin-like growth fa

144 ndary prevention of deep-vein thrombosis and pulmonary embolism has been shown in phase 3 trials.

145 p vein thrombosis (DVT) and its complication pulmonary embolism have high morbidity reducing quality

146 re were no consistent differences in risk of pulmonary embolism, hip fracture, or depression as a fun

147 (V/Q) scanning is often used to investigate pulmonary embolism; however, it has well-recognized limi

148 is (HR, 0.66; 95% CI, 0.47-0.92; P=0.01) and pulmonary embolism (HR, 0.66; 95% CI, 0.41-1.06; P=0.08)

149 ndomly assigned to cardiac arrest induced by pulmonary embolism, hypoxia, or primary arrhythmia.

150 ed a first episode of symptomatic unprovoked pulmonary embolism (ie, with no major risk factor for th

151 Pulmonary surgery, pulmonary embolism, IGCCCG poor prognosis, and smoking i

152 6.9%), pulmonary infection in 80 (6.5%), and pulmonary embolism in 47 (3.8%) patients.

153 n [3%] in the control group), of which one-a pulmonary embolism in a 64-year-old male patient after 1

154 us thromboembolism, deep vein thrombosis, or pulmonary embolism in adults were included, as were inte

155 ophylaxis decreases deep vein thrombosis and pulmonary embolism in medical-surgical critically ill pa

156 We performed a systematic workup for pulmonary embolism in patients admitted to 11 hospitals

157 e 3-month incidence of symptomatic UEDVT and pulmonary embolism in patients with a normal diagnostic

158 based guidelines for evaluation of suspected pulmonary embolism in pregnancy using the Grades of Reco

159 little attention to a diagnostic workup for pulmonary embolism in these patients.

160 bolism in TPKA studies and for VTE, DVT, and pulmonary embolism in TPHA studies.

161 A studies but less heterogeneity for DVT and pulmonary embolism in TPKA studies and for VTE, DVT, and

162 (2%) patients died from adverse events; one (pulmonary embolism in treatment group A) was possibly re

163 postoperative mortality rate was 3% (due to pulmonary embolisms in 2 patients and hemorrhage after p

164 92; 95% confidence interval, 1.80-2.05), and pulmonary embolism (incidence rate ratio, 1.80; 95% conf

165 Among patients with pulmonary embolism, including those who were hemodynamic

166 Following approval of rivaroxaban for the pulmonary embolism indication, patients with deep-vein t

167 lly treated with thrombolytic therapy during pulmonary embolism-induced cardiopulmonary arrest and di

168 ective analysis of 143 patients suspected of pulmonary embolism investigated with 3 different scanner

169 c therapy in patients with intermediate-risk pulmonary embolism is controversial.

170 inical diagnosis of deep-vein thrombosis and pulmonary embolism is nonspecific, integrated diagnostic

171 Massive acute pulmonary embolism is the clearest indication for the ad

172 gulation after a first episode of unprovoked pulmonary embolism is uncertain.

173 hrombosis (DVT) with its major complication, pulmonary embolism, is a global health problem.

174 y hypertension, a rare complication of acute pulmonary embolism, is characterized by fibrothrombotic

175 ased thrombin generation and protection from pulmonary embolism, leading to prolonged survival.

176 enefit" (all strokes, systemic embolism, MI, pulmonary embolism, major bleeding, and all-cause death)

177 ncrease survival in an otherwise fatal mouse pulmonary embolism model.

178 ing during BAT in one [3%] patient each were pulmonary embolism, myocardial infarction, urinary obstr

179 ths were noted on study due to pneumonia and pulmonary embolism (n = 1 each).

180 bosis (OR 2.55, 1.54-4.23, p<0.0001) but not pulmonary embolism (no events).

181 en), respiratory failure (four vs none), and pulmonary embolism (none vs three).

182 Pulmonary embolism occurred in 47 patients (1.3%) and wa

183 igation); subsequent deep-vein thrombosis or pulmonary embolism occurred in 9.3% (5/54) and 8.9% (5/5

184 tionally, a serious adverse event of grade 4 pulmonary embolism occurred in one patient.

185 No pulmonary embolism occurred.

186 r hospital mortality was not impacted by the pulmonary embolism occurrence.

187 Pulmonary embolism often causes cardiac arrest.

188 mab group (one interstitial lung disease and pulmonary embolism, one bronchopneumonia, and one pulmon

189 current venous thromboembolism manifested as pulmonary embolism or deep vein thrombosis.

190 quently diagnosed in subjects with suspected pulmonary embolism or DVT and account for one-fourth to

191 mages not shown) and revealed no evidence of pulmonary embolism or lower extremity thrombus.

192 ent of the composite, and death unrelated to pulmonary embolism or major bleeding, at 18 and 42 month

193 as associated with a lower risk of recurrent pulmonary embolism (OR, 0.40; 95% CI, 0.22-0.74; 1.17% [

194 posite of any deep vein thrombosis, nonfatal pulmonary embolism, or all-cause death.

195 was found between pulmonary tuberculosis and pulmonary embolism, or between extrapulmonary tuberculos

196 ohol consumption, acute pericardial disease, pulmonary embolism, or other acute pulmonary disease).

197 us thromboembolism, deep vein thrombosis, or pulmonary embolism outcomes.

198 mbolytic therapy vs anticoagulant therapy in pulmonary embolism patients.

199 C), pulmonary hypertension (1B), symptomatic pulmonary embolism (PE) (1C), right ventricular (RV) inf

200 on-LR and LRnon-neonates, respectively), and pulmonary embolism (PE) (P < .001; 19.6% and 3.2% in Non

201 ed all patients who were suspected of having pulmonary embolism (PE) and who underwent CT pulmonary a

202 Pulmonary embolism (PE) can be a severe disease and is d

203 While pulmonary embolism (PE) causes approximately 100 000-180

204 anguage processing (NLP) model in extracting pulmonary embolism (PE) findings from thoracic computed

205 t is not clear whether mortality after acute pulmonary embolism (PE) has decreased over time.

206 d stroke, the treatment and outcome of acute pulmonary embolism (PE) have remained relatively unchang

207 mance of different diagnostic strategies for pulmonary embolism (PE) in patient subgroups is unclear.

208 to 180,000 deaths occur annually from acute pulmonary embolism (PE) in the United States.

209 Pulmonary embolism (PE) is a leading cause of maternal m

210 Pulmonary embolism (PE) is a serious and prevalent cause

211 The clinical diagnosis of acute pulmonary embolism (PE) is frequently considered in pati

212 ong-term effect of thrombolytic treatment of pulmonary embolism (PE) is unknown.

213 The identification of pulmonary embolism (PE) on computed tomography scans per

214 Vena cava filter (VCF) placement for pulmonary embolism (PE) prophylaxis in trauma is controv

215 Pulmonary embolism (PE) remains a major contributor to g

216 tients with deep venous thrombosis (DVT) and pulmonary embolism (PE) were markedly higher than for th

217 The rates of deep vein thrombosis (DVT), pulmonary embolism (PE), and VTE within 30 days of the i

218 enous thrombosis (DVT) and its complication, pulmonary embolism (PE), and whether elevated fibrinogen

219 ostic strategy of clinically suspected acute pulmonary embolism (PE), but its clinical usefulness is

220 ), comprising deep vein thrombosis (DVT) and pulmonary embolism (PE), is a common, potentially lethal

221 ), comprising deep vein thrombosis (DVT) and pulmonary embolism (PE), is a significant source of mort

222 isk and the outcomes of all-cause mortality, pulmonary embolism (PE)-related mortality, and VTE rates

223 caval filters (IVCFs) may prevent recurrent pulmonary embolism (PE).

224 of developing deep vein thrombosis (DVT) and pulmonary embolism (PE).

225 /Q) imaging in patients with suspected acute pulmonary embolism (PE).

226 to be one of the strongest risk factors for pulmonary embolism (PE).

227 ced after a first unprovoked proximal DVT or pulmonary embolism (PE).

228 isease compared with more proximally located pulmonary embolism (PE).

229 formance of V/Q imaging for the diagnosis of pulmonary embolism (PE).

230 C) filters are widely used for prevention of pulmonary embolism (PE).

231 phy and may result in proximal thrombosis or pulmonary embolism (PE).

232 the vascular system (deep venous thrombosis/pulmonary embolism, peripheral vascular disease, hyperco

233 In patients with hemodynamically significant pulmonary embolism, physiological fibrinolysis fails to

234 The most frequently missed diagnoses were pulmonary embolism, pneumonia, secondary peritonitis, in

235 529 patients from the Prognostic Factors for Pulmonary Embolism (PREP) study (validation cohort).

236 osite of symptomatic deep-vein thrombosis or pulmonary embolism, progression or recurrence of superfi

237 terms of symptomatic deep-vein thrombosis or pulmonary embolism, progression or recurrence of superfi

238 inal bleeding (1.4% versus 1.8%; P=0.35), or pulmonary embolism rates (18.4% versus 17.9%; P=0.72).

239 Complications of CRT include pulmonary embolism, recurrent deep venous thrombosis, lo

240 ons (nonfatal myocardial infarction, stroke, pulmonary embolism, renal failure, or bowel infarction)

241 ons (nonfatal myocardial infarction, stroke, pulmonary embolism, renal failure, or bowel infarction)

242 prognostic and therapeutic plan is through a Pulmonary Embolism Response Team, which combines experti

243 In patients with pulmonary embolism, right ventricular dysfunction is ass

244 tionated heparin) thromboprophylaxis lowered pulmonary embolism risk (hazard ratio, 0.51; 95% CI, 0.2

245 1 [95% CI, 0.41, 0.63]; p<0.0001; I=77%) and pulmonary embolism (risk ratio, 0.52 [95% CI, 0.28, 0.97

246 0.39, 1.00]; p=0.05; I=53%) and symptomatic pulmonary embolism (risk ratio, 0.58 [95% CI, 0.34, 0.97

247 ow-molecular-weight heparin reduced rates of pulmonary embolism (risk ratio, 0.62 [95% CI, 0.39, 1.00

248 retest probability of PE who do not meet all Pulmonary Embolism Rule-Out Criteria.

249 w pretest probability of PE and who meet all Pulmonary Embolism Rule-Out Criteria.

250 rate/low risk of embolism according to Wells pulmonary embolism score, selected from the emergency se

251 several established risk factors for DVT and pulmonary embolism separately.

252 mechanical ventilation, respiratory failure, pulmonary embolism, sepsis, or death.

253 -causality grade 3 and 4 adverse events were pulmonary embolism (seven [3%]), prolonged electrocardio

254 The combination of the simplified Pulmonary Embolism Severity Index and brain natriuretic

255 The final model included the simplified Pulmonary Embolism Severity Index, cardiac troponin I, b

256 rude comparison of patients with and without pulmonary embolism shows no difference in length of stay

257 The clinical significance of subsegmental pulmonary embolism (SSPE) remains to be determined.

258 autonomic (sympathetic) reflexes, can cause pulmonary embolism, stroke, and, in severe cases, death.

259 In patients with acute pulmonary embolism, systemic thrombolysis improves right

260 r and fewer had active cancer or concomitant pulmonary embolism than those in the standard anticoagul

261 ned as patients with deep vein thrombosis or pulmonary embolism) that occurred during the patient's i

262 mong hospitalized patients with severe acute pulmonary embolism, the use of a retrievable inferior ve

263 o [8%]), dyspnoea (three [12%] vs one [4%]), pulmonary embolism (three [12%] vs 0), fatigue (one [4%]

264 in the palbociclib plus letrozole group were pulmonary embolism (three [4%] patients), back pain (two

265 There were four instances of pulmonary embolism, three aortic dissections (Stanford t

266 (Pulmonary Embolism Thrombolysis study [PEITHO]; NCT00639

267 The PEITHO (Pulmonary Embolism Thrombolysis) trial was a randomized

268 In intermediate-risk pulmonary embolism trials, thrombolysis was associated w

269 ion (two of eight), diarrhea (two of eight), pulmonary embolism (two of eight), pulmonary hypertensio

270 Risk stratification for acute pulmonary embolism using imaging presence of right ventr

271 of thrombin generation in a murine model of pulmonary embolism using our protease-activated peptide

272 many patients with deep vein thrombosis and pulmonary embolism (venous thromboembolism, VTE), biomar

273 , pneumonia, sepsis, deep venous thrombosis, pulmonary embolism, venous thromboembolism, and myocardi

274 In the entire cohort, the prevalence of pulmonary embolism was 17.3% (95% confidence interval, 1

275 Pulmonary embolism was identified in 45 of the 355 patie

276 Among the remaining 230 patients, pulmonary embolism was identified in 97 (42.2%).

277 Pulmonary embolism was identified in nearly one of every

278 Pulmonary embolism was induced 30 min or 2 d after DVT b

279 Pulmonary embolism was induced by jugular vein infusion

280 Pulmonary embolism was lower compared with warfarin for

281 d patients who needed a computed tomography, pulmonary embolism was more common than expected.

282 Pulmonary embolism was more frequent in black patients,

283 urces; no subsequent deep-vein thrombosis or pulmonary embolism was observed in fondaparinux patients

284 A diagnosis of pulmonary embolism was ruled out in 330 of the 560 patie

285 The diagnosis of pulmonary embolism was ruled out in patients who had a l

286 rombosis, but not risk for death or nonfatal pulmonary embolism, was reduced with factor Xa inhibitor

287 Patients diagnosed with pulmonary embolism were all treated with therapeutic ant

288 ts with deep-vein thrombosis and concomitant pulmonary embolism were also eligible; however, those wi

289 vival following collagen/epinephrine-induced pulmonary embolism were also observed in Dicer1-deficien

290 ch risk factors for deep vein thrombosis and pulmonary embolism were assessed.

291 and pooled incidence rates of VTE, DVT, and pulmonary embolism were estimated using random-effects m

292 also eligible; however, those with isolated pulmonary embolism were not included.

293 th cancer or with intermediate- to high-risk pulmonary embolism, were underrepresented in the Phase I

294 d rhythm analysis: 32 mm (95% CI, 29-36) for pulmonary embolism which was significantly larger than b

295 ver, findings may not apply to patients with pulmonary embolism who are hemodynamically stable withou

296 patients with a first episode of unprovoked pulmonary embolism who received 6 months of anticoagulan

297 Patients without pulmonary embolism who underwent CT pulmonary angiograph

298 ic deep-vein thrombosis or acute symptomatic pulmonary embolism (with or without deep-vein thrombosis

299 ented proximal deep vein thrombosis (DVT) or pulmonary embolism, with a life expectancy greater than

300 e hypothesis that filters reduce the risk of pulmonary embolism, with a point estimate suggesting inc

301 ified stroke, transient ischemic attack, and pulmonary embolism) yielded a 44% higher annual risk tha